Otsuka

Japan - Tokushima

Biotechnology2 H-1B visas (FY2023)

Website LinkedIn Careers Page

Focus: Small Molecules

Otsuka is a life sciences company focused on Small Molecules.

NeurologyNephrologyHematologyPsychiatryOncology

Open Jobs

Products & Portfolio (35)

15 discontinued products not shown

mania, is unclear. However, the efficacy of aripiprazole in the listed indications could be mediated through a combination of partial agonist activity at D 2 and 5-HT 1A receptors and antagonist activity at 5-HT 2A receptors.

SMINTRAMUSCULAR · SUSPENSION, EXTENDED RELEASE

unknown. The efficacy of aripiprazole could be mediated through a combination of partial agonist activity at dopamine D 2 and serotonin 5-HT 1A receptors and antagonist activity at 5-HT 2A receptors.

schizophreniafor the treatment of schizophrenia

SMINTRAMUSCULAR · FOR SUSPENSION, EXTENDED RELEASE

unknown. The efficacy of aripiprazole could be mediated through a combination of partial agonist activity at dopamine D 2 and serotonin 5-HT 1A receptors and antagonist activity at 5-HT 2A receptors.

schizophreniafor the treatment of schizophreniafor treatment of schizophrenia

2013

ACETIC ACID 0.25% IN PLASTIC CONTAINER

acetic acid, glacial

LOE Approaching

IRRIGATION, URETHRAL · SOLUTION

1976

AMINOSYN II 10% IN PLASTIC CONTAINER

isoleucine, leucine, lysine acetate, methionine, phenylalanine, threonine, tryptophan, valine, alanine, arginine, aspartic acid, glutamic acid, histidine, proline, serine, n-acetyltyrosine, and glycine

LOE Approaching

INJECTION · INJECTABLE

CLINICAL PHARMACOLOGY Aminosyn II, Sulfite-Free, (an amino acid injection) provides crystalline amino acids to promote protein synthesis and wound healing, and to reduce the rate of endogenous protein catabolism. Aminosyn II, given by central venous infusion in combination with concentrated dextrose, electrolytes, vitamins, trace metals, and ancillary fat supplements, constitutes total parenteral nutrition (TPN). Aminosyn II can also be administered by peripheral vein with dextrose and maintenance electrolytes. Intravenous fat emulsion may be substituted for part of the carbohydrate calories during either TPN or peripheral vein administration of Aminosyn II.

1991

AMINOSYN II 15% IN PLASTIC CONTAINER

LOE Approaching

INJECTION · INJECTABLE

1991

AMINOSYN-PF 10%

isoleucine, leucine, lysine acetate, methionine, phenylalanine, threonine, tryptophan, valine, alanine, arginine, aspartic acid, glutamic acid, glycine, histidine, proline, serine, taurine, and tyrosine

LOE Approaching

INJECTION · INJECTABLE

CLINICAL PHARMACOLOGY Aminosyn-PF 10%, Sulfite-Free, (an amino acid injection — pediatric formula) contains a mixture of essential and nonessential amino acids as well as taurine. The amino acid composition has been specifically formulated to provide a well-tolerated nitrogen source for nutritional support and therapy for infants and young children. When administered in conjunction with a cysteine hydrochloride additive, Aminosyn-PF 10% results in plasma amino acid concentrations approximating a profile consistent with that of a breast-fed infant. The rationale for Aminosyn-PF 10% is based on the observation of inadequate levels of essential amino acids in the plasma of infants receiving total parenteral nutrition (TPN) using conventional amino acid solutions. Clinical studies in infants who required TPN therapy showed that infusion of Aminosyn-PF 10% resulted in plasma amino acid concentrations approximating those of normal breast or formula fed infants. In addition, weight gains, nitrogen balance, and serum protein concentrations were consistent with an improving nutritional status. When infused with hypertonic dextrose as a calorie source, supplemented with cysteine hydrochloride, electrolytes, vitamins, and minerals, Aminosyn-PF 10% provides TPN for infants and young children, with the exception of essential fatty acids. It is thought that the acetate from lysine acetate under the conditions of parenteral nutrition, does not impact net acid-base balance when renal and respiratory functions are normal. Clinical evidence seems to support this thinking; however, confirmatory experimental evidence is not available. The amounts of sodium and acetate in Aminosyn-PF 10% are not of clinical significance. The addition of a cysteine hydrochloride additive will contribute to the chloride load. The electrolyte content of any additives that are introduced should be carefully considered and included in input computations. The human newborn conjugates bile with taurine which becomes the primary method of biliary excretion. Taurine deficiency because of its effect on bile salt conjugation and, therefore, on bile salt flow may be of major importance in the genesis of cholestasis. Taurine has also been shown to play a role in central nervous system development.

nitrogenweight losstreat negative nitrogen balance in infants+3 more

1986

AMINOSYN-PF 7%

LOE Approaching

INJECTION · INJECTABLE

CLINICAL PHARMACOLOGY Aminosyn-PF 7% Sulfite-Free, (an amino acid injection — pediatric formula) contains a mixture of essential and nonessential amino acids as well as taurine. The amino acid composition has been specifically formulated to provide a well-tolerated nitrogen source for nutritional support and therapy for infants and young children. When administered in conjunction with a cysteine hydrochloride additive, Aminosyn-PF 7% results in plasma amino acid concentrations approximating a profile consistent with that of a breast-fed infant. The rationale for Aminosyn-PF 7% is based on the observation of inadequate levels of essential amino acids in the plasma of infants receiving total parenteral nutrition (TPN) using conventional amino acid solutions. Clinical studies in infants who required TPN therapy showed that infusion of Aminosyn-PF 7% resulted in plasma amino acid concentrations approximating those of normal breast or formula fed infants. In addition, weight gains, nitrogen balance, and serum protein concentrations were consistent with an improving nutritional status. When infused with hypertonic dextrose as a calorie source, supplemented with cysteine hydrochloride, electrolytes, vitamins, and minerals, Aminosyn-PF 7% provides TPN for infants and young children, with the exception of essential fatty acids. It is thought that the acetate from lysine acetate under the conditions of parenteral nutrition, does not impact net acid-base balance when renal and respiratory functions are normal. Clinical evidence seems to support this thinking; however, confirmatory experimental evidence is not available. The amounts of sodium and acetate in Aminosyn-PF 7% are not of clinical significance. The addition of a cysteine hydrochloride additive will contribute to the chloride load. The electrolyte content of any additives that are introduced should be carefully considered and included in input computations. The human newborn conjugates bile with taurine which becomes the primary method of biliary excretion. Taurine deficiency because of its effect on bile salt conjugation and, therefore, on bile salt flow may be of major importance in the genesis of cholestasis. Taurine has also been shown to play a role in central nervous system development.

nitrogenweight losstreat negative nitrogen balance in infants+3 more

INJECTION · INJECTABLE

Alkylating Activity

leukemia

1999

DEXTROSE 10% IN PLASTIC CONTAINER

dextrose monohydrate

LOE Approaching

INJECTION · INJECTABLE

CLINICAL PHARMACOLOGY When administered intravenously, solutions containing carbohydrate in the form of dextrose restore blood glucose levels and provide calories. Carbohydrate in the form of dextrose may aid in minimizing liver glycogen depletion and exerts a protein sparing action. Dextrose Injection, USP undergoes oxidation to carbon dioxide and water. Water is an essential constituent of all body tissues and accounts for approximately 70% of total body weight. Average normal adult daily requirement ranges from two to three liters (1.0 to 1.5 liters each for insensible water loss by perspiration and urine production, respectively). Water balance is maintained by various regulatory mechanisms. Water distribution depends primarily on the concentration of electrolytes in the body compartments, and sodium (Na) plays a major role in maintaining physiologic equilibrium.

1979

DEXTROSE 20% IN PLASTIC CONTAINER

dextrose

LOE Approaching

INJECTION · INJECTABLE

parenterally. Dextrose is oxidized to carbon dioxide and water, yielding energy.

1982

DEXTROSE 30% IN PLASTIC CONTAINER

dextrose

LOE Approaching

INJECTION · INJECTABLE

parenterally. Dextrose is oxidized to carbon dioxide and water, yielding energy.

1985

View all 35 products

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 93 approved products, 100 clinical trials

Top TAs: Neurology, Oncology, Nephrology

H-1B (2023): 2 approvals

Portfolio Health

Launch1 (1%)

Growth1 (1%)

Peak5 (5%)

LOE Approaching85 (91%)

Post-LOE1 (1%)

93 total products

Therapeutic Area Focus

Neurology

7 marketed209 pipeline

Oncology

2 marketed52 pipeline

Nephrology

7 marketed30 pipeline

29 pipeline

28 pipeline

16 pipeline

14 pipeline

2 marketed10 pipeline

Marketed

Pipeline

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub